Isomorphic Labs raises $5bn in Series C funding for AI drug discovery
Isomorphic Labs has raised $5 billion in a Series C round to advance its AI drug discovery platform. The funding follows a $2.1 billion Series B and supports the company's move into clinical trials.
Isomorphic Labs, the artificial intelligence drug discovery platform spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round. The company stated that the new capital will be used to advance its drug candidates to clinical trials, marking a significant step in its transition from research and development to human testing.
The funding round was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz joined the round as a new investor, while all of the company’s existing backers also participated. These existing investors include Alphabet’s venture divisions GV and Capital G, as well as Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
This latest raise follows a $2.1 billion Series B round that concluded in May. Isomorphic Labs did not disclose its new valuation following the transaction. However, Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.
Isomorphic Labs operates by building an AI drug-design engine. This system uses a series of simulation AI models to explore various areas of chemistry, assisting the company in designing potential therapeutics. The technology builds directly on DeepMind’s breakthrough AlphaFold protein-folding AI model.
AlphaFold is a system that predicts the three-dimensional structure of proteins using only their genetic sequence. This foundational work has allowed Isomorphic Labs to apply computational approaches to pharmaceutical research, aiming to accelerate the discovery of new medicines.
The company, whose work builds on the AlphaFold model, said its program has yielded positive preclinical results in oncology and immunology. These results indicate that the AI-designed candidates are showing promise in early-stage testing outside of human subjects.
Isomorphic Labs has already struck deals with several major pharmaceutical companies. Partnerships have been established with Eli Lilly, Novartis, and Johnson & Johnson. These collaborations are central to the company’s strategy of leveraging its AI platform to develop new treatments.
The Series C is Isomorphic’s first fundraise since founder and CEO Demis Hassabis left his position as head of DeepMind. Hassabis moved into a chairman role at DeepMind to focus exclusively on drug discovery. This shift in leadership allowed him to dedicate his full attention to the Isomorphic Labs enterprise.
Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold. The prize recognised the system’s ability to predict protein structures with high accuracy, a capability that has since been applied to drug discovery efforts at the spinoff company.
The newly acquired capital will support continued refinement of the underlying drug design engine. Management intends to use the resources to transition promising internal candidates through regulatory phases and into human clinical trials. This expansion is a key part of the company’s long-term strategy.
The funding also allows the company to foray into more types of medicine. By expanding its therapeutic modalities, Isomorphic Labs aims to address a broader range of diseases using its AI-driven approach. This diversification is supported by the substantial investment from global venture capital and sovereign wealth funds.
The participation of the UK Sovereign AI Fund highlights the strategic importance of AI in scientific research. The fund’s involvement underscores the government’s interest in advancing AI capabilities that have tangible applications in healthcare and life sciences.
Alphabet’s continued support through GV and Capital G reflects the parent company’s commitment to the spinoff’s success. The involvement of multiple venture capital firms, including Thrive Capital and MGX, indicates strong confidence in the company’s trajectory and its ability to deliver commercial results.
The $5 billion raise places Isomorphic Labs among the most heavily funded AI startups in the pharmaceutical sector. The company’s ability to attract such significant capital is a testament to the growing recognition of AI’s potential to transform drug discovery.
As the company moves toward clinical trials, the focus will shift from algorithmic development to rigorous scientific validation. The positive preclinical results in oncology and immunology provide a foundation for this next phase, although the path to approved medicines remains long and complex.
The partnerships with Eli Lilly, Novartis, and Johnson & Johnson will likely play a crucial role in this process. These pharmaceutical giants bring extensive experience in clinical trials, regulatory navigation, and global drug distribution, complementing Isomorphic Labs’ AI expertise.
The company’s approach combines computational power with biological insight. By using AI to simulate chemical interactions, Isomorphic Labs aims to identify promising drug candidates more efficiently than traditional methods. This efficiency is a key driver of the investment interest in the company.
The spinout from DeepMind in 2021 was designed to allow the company to operate with greater agility and focus. The separation from Google’s broader AI research efforts has enabled Isomorphic Labs to build a specialised team and infrastructure dedicated to drug discovery.
The recent funding round also signals a broader trend in the tech industry. AI companies are increasingly partnering with established industries, including healthcare, to apply their technologies to real-world problems. The pharmaceutical sector is a prime example of this convergence.
Isomorphic Labs’ journey from a research project to a major funded enterprise illustrates the rapid pace of innovation in AI. The company’s progress in just a few years has attracted significant attention from investors and industry leaders alike.
The next steps for the company will involve managing the transition to clinical trials. This phase requires careful planning, regulatory compliance, and collaboration with pharmaceutical partners. The $5 billion in funding provides the resources needed to navigate this complex process.
The involvement of diverse investors, from venture capital firms to sovereign funds, reflects the global nature of the AI drug discovery market. The company’s success will depend on its ability to translate AI insights into viable medicines that can benefit patients worldwide.
The positive preclinical results reported by the company are a significant milestone. They demonstrate that the AI-driven approach is yielding tangible scientific outcomes. These results will be closely watched by the scientific community and investors as the company moves forward.
The company’s leadership, including Demis Hassabis, remains focused on the long-term goal of transforming drug discovery. The recent funding round provides the financial stability and resources needed to pursue this ambitious vision. The next few years will be critical in determining the company’s success.
Isomorphic Labs’ story is a compelling example of how AI is reshaping traditional industries. The company’s ability to attract major investment and form strategic partnerships highlights the potential of AI to drive innovation in healthcare. The industry will be watching closely as the company advances its drug candidates to clinical trials.
Elected News
-
Bangladesh Seeks UN Women Support on Digital Harassment and Women’s Empowerment
-
Bangladesh, Australia Discuss Human Trafficking, Irregular Migration and Rohingya Crisis
-
Bangladesh Plans Internet-Free Access to Mobile Banking and Financial Apps
-
DU to Open Undergraduate Admission Applications on 11 November, Tests Begin 5 December